Several studies found that various doses of intranasal insulin lead to a mild decrease in blood glucose levels in healthy young adults (35–37), whereas no such effect was found in overweight or obese patients (38) and patients with type 2 diabetes (39). Here, INS is linked to type 2 diabetes mellitus.